CC
ARQT icon

Centiva Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Centiva Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,984
Closed -$67.8K – 1760
2023
Q4 		$67.8K Sell
20,984
-189,016
-90% -$514K ﹤0.01% 1623
2023
Q3 		$1.12M Buy
210,000
+120,000
+133% +$1.02M 0.06% 580
2023
Q2 		$858K Sell
90,000
-110,000
-55% -$1.22M 0.04% 625
2023
Q1 		$2.2M Buy
+200,000
New +$2.89M 0.12% 373
2022
Q4 		– Sell
-50,000
Closed -$956K – 1361
2022
Q3 		$956K Buy
+50,000
New +$1.13M 0.07% 643
2022
Q2 		– Sell
-25,729
Closed -$496K – 1680
2022
Q1 		$496K Buy
+25,729
New +$435K 0.03% 982

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return